These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 21161752)
41. Inhibitory role of oxytocin in psychostimulant-induced psychological dependence and its effects on dopaminergic and glutaminergic transmission. Yang JY; Qi J; Han WY; Wang F; Wu CF Acta Pharmacol Sin; 2010 Sep; 31(9):1071-4. PubMed ID: 20729875 [TBL] [Abstract][Full Text] [Related]
43. Can we predict psychostimulant use in youths? A study with structural equation modeling analysis. Becoña E; López-Durán A; Fernández del Río E; Martínez Ú; Fraga J; Osorio J; Arrojo M; López-Crecente F; Domínguez MN Adicciones; 2012; 24(4):339-46. PubMed ID: 23248029 [TBL] [Abstract][Full Text] [Related]
44. Anhedonia in depression: biological mechanisms and computational models. Cooper JA; Arulpragasam AR; Treadway MT Curr Opin Behav Sci; 2018 Aug; 22():128-135. PubMed ID: 29503842 [TBL] [Abstract][Full Text] [Related]
45. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. Lee TH; Szabo ST; Fowler JC; Mannelli P; Mangum OB; Beyer WF; Patkar A; Wetsel WC Drug Alcohol Depend; 2012 Jul; 124(1-2):11-8. PubMed ID: 22356892 [TBL] [Abstract][Full Text] [Related]
46. Predicting treatment outcome in stimulant dependence. Reske M; Paulus MP Ann N Y Acad Sci; 2008 Oct; 1141():270-83. PubMed ID: 18991963 [TBL] [Abstract][Full Text] [Related]
47. Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder. Petković B; Kesić S; Pešić V Curr Pharm Des; 2020; 26(4):466-484. PubMed ID: 31939725 [TBL] [Abstract][Full Text] [Related]
48. Conceptualizing anhedonias and implications for depression treatments. Winer ES; Jordan DG; Collins AC Psychol Res Behav Manag; 2019; 12():325-335. PubMed ID: 31191054 [TBL] [Abstract][Full Text] [Related]
49. Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits. D'Souza MS Front Psychiatry; 2019; 10():509. PubMed ID: 31396113 [TBL] [Abstract][Full Text] [Related]
50. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Clark KH; Wiley CA; Bradberry CW Neurotox Res; 2013 Feb; 23(2):174-88. PubMed ID: 22714667 [TBL] [Abstract][Full Text] [Related]
52. Characterization of the Brain Functional Architecture of Psychostimulant Withdrawal Using Single-Cell Whole-Brain Imaging. Kimbrough A; Kallupi M; Smith LC; Simpson S; Collazo A; George O eNeuro; 2021; 8(6):. PubMed ID: 34580158 [TBL] [Abstract][Full Text] [Related]
53. Hyperthermia in psychostimulant overdose. Callaway CW; Clark RF Ann Emerg Med; 1994 Jul; 24(1):68-76. PubMed ID: 8010552 [TBL] [Abstract][Full Text] [Related]
54. "This drug turned me into a robot": an actor-network analysis of a web-based ethnographic study of psychostimulant use. Robitaille C Can J Public Health; 2018 Dec; 109(5-6):653-661. PubMed ID: 30465287 [TBL] [Abstract][Full Text] [Related]
55. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Markou A; Kenny PJ Neurotox Res; 2002 Jun; 4(4):297-313. PubMed ID: 12829420 [TBL] [Abstract][Full Text] [Related]
56. Tripping for tests: psychostimulant misuse among university students - extra. Hickman RA Br J Psychiatry; 2010 Jul; 197(1):60. PubMed ID: 20592435 [No Abstract] [Full Text] [Related]
57. Substance misuse prevention: addressing anhedonia. Sussman S; Leventhal A New Dir Youth Dev; 2014; 2014(141):45-56, 10. PubMed ID: 24753277 [TBL] [Abstract][Full Text] [Related]
58. A mechanistic overview of approaches for the treatment of psychostimulant dependence. Jensen KL; Jensen SB; Madsen KL Front Pharmacol; 2022; 13():854176. PubMed ID: 36160447 [TBL] [Abstract][Full Text] [Related]